Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 11Unknown 6Recruiting 4Terminated 3Active not recruiting 3

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Rare Tumor 1Neoplasms 1

Interventions

Specimen Handling 336Magnetic Resonance Spectroscopy 333Radiotherapy 315Cyclophosphamide 295pembrolizumab 282Cisplatin 266Carboplatin 245Drug Therapy 237Blood Specimen Collection 233Biopsy 206Bevacizumab 187Gemcitabine 177venetoclax 172Radiosurgery 169Capecitabine 165Oxaliplatin 163fludarabine 160Nivolumab 156Paclitaxel 155Standard of Care 137Surveys and Questionnaires 131Surgical Procedures, Operative 130Dexamethasone 127Fluorouracil 125Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104atezolizumab 101Azacitidine 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × OTHER × dacomitinib × Clear all
NCT06486142 2026-05-14

ERIS

Region Skane

Phase 3 Recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
770 enrolled

Rare Tumor

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

NCT05271916 2023-04-19

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Shanghai Chest Hospital

Phase 1/2 Recruiting
140 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡